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Abstract
Background
Fibromyalgia (FM) patients frequently complain of cognitive problems, but it remains unclear
whether these cognitive complaints can be attributed to a dysfunction of the central nervous
system or if they can be explained by other factors associated with the disease, such as
depression, anxiety and sleep dysfunction.
Methods
One hundred and ten patients with FM were compared with thirty-three patients diagnosed
with a depressive disorder (DD) and fifty healthy controls (HC). Several measures of atten-
tion and executive functions were used to make these comparisons and the patients were
also asked to complete questionnaires on depression, anxiety and sleep quality. Univariate
analyses of covariance (ANCOVA) were performed to identify and control confounders and
multiple linear models were used to examine the effects of fibromyalgia and depression on
cognitive measures.
Results
FM and HC differed significantly with respect to depression, anxiety and sleep dysfunction,
whereas FM and DD did not differ in terms of symptoms of depression and anxiety. How-
ever, FM was associated with a worse quality of sleep than DD. Comparisons of cognitive
performance between groups showed that short-term and working memory and inattention
measures were only associated with symptoms of depression, whereas selective attention
was associated with both depression and fibromyalgia, and processing speed, cognitive
flexibility and inhibitory control showed a significant interaction between depression and
fibromyalgia. Moreover, cognitive flexibility and inhibition abilities were specifically associ-
ated with FM.
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Conclusion
FM patients show a cluster of cognitive impairment in the attentional and executive domains,
although some of the symptoms observed could be explained by the severity of the symp-
toms of depression, while others seem to depend on the effects of fibromyalgia. Implications
of the findings for the understanding and management of cognitive impairment of FM
patients are discussed.
Introduction
Fibromyalgia is a chronic disorder characterised by the presence of generalised and diffuse
pain. It is generally accompanied by somatic symptoms, fatigue, waking unrefreshed, depres-
sion and cognitive dysfunction [1]. Although self-reported cognitive disturbances are widely
recognised in patients with fibromyalgia, there is no absolute consensus among researchers
regarding patient performance with respect to objective cognitive measures [2]. As a result,
many studies have evidenced cognitive impairment in patients with fibromyalgia compared
with control groups, with fibromyalgia patients mainly exhibiting problems with working
memory processes and/or in their attentional and executive domains, as well as in processing
speed [3–8]. However, other studies have failed to find any impaired performance in the cog-
nitive functions of these patients [9–12]. A couple of recent meta-analytical reviews under-
taken with a chronic pain population have provided evidence of impairment of working
memory and also of three other components of executive functions: response inhibition, com-
plex executive function and set shifting [13,14]. Whatever the approach adopted, these authors
also highlighted the high risk of bias in the studies included.
Psychiatric symptoms such as depressive and anxious disorders as well as sleep dysfunction
have frequently been associated with fibromyalgia [15–18]. It has been hypothesised that cog-
nitive dysfunction may be correlated with these psychiatric comorbidities. Indeed, the pres-
ence of depression in patients with fibromyalgia clearly constitutes a potential confounding
factor given the strong evidence for neuropsychological impairment in depressed patients,
who typically show deficits in attention, memory, psychomotor speed, processing speed and
executive function [19–21]. Even so, the role of mood disorders has not always been taken into
account in studies of cognitive dysfunction associated with fibromyalgia. Landro et al [12]
reported that both depressed patients and fibromyalgia patients showed a similar pattern of
deficient memory. This was particularly evident in long-term memory tasks requiring effortful
processing, in which their memory was significantly impaired compared to healthy controls.
Similarly, Su¨hr et al [22] found that depression was significantly related to memory perfor-
mance in their study that compared samples of patients with fibromyalgia, chronic pain disor-
ders and healthy controls; furthermore, these groups were not different in cognitive
performance after controlling for fatigue, pain and depression. Nevertheless, a number of
other studies found no association between emotional factors and cognitive function in fibro-
myalgia patients [7,23–25].
Sleep dysfunction is another factor that should be taken into account in studies of cognitive
dysfunction in fibromyalgia. Research has confirmed that these patients suffer from poorer
sleep quality than the general population and also non-restorative sleep [26–28]. Studies exam-
ining cognitive performance in people with sleep disorders have found an association between
disturbed sleep or insomnia and reduced working memory. They have also noted significant
impairment in attention and episodic memory [29,30]. This symptom has, however, been
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largely ignored in research into cognitive functions, both in general for patients with chronic
pain and more specifically for patients with fibromyalgia [14]. In addition, it should be added
that when this variable has been analysed, mixed results have been obtained. To our knowl-
edge, only one study has so far identified a significant association between objective cognitive
measures and sleep dysfunction [31]; they were not identified in the others [3,32,33].
The aim of this study was to add new evidence to previous research and to evaluate the asso-
ciation between fibromyalgia and cognitive impairment, particularly in the domains of atten-
tion and executive functions, controlling for the effects of depression, anxiety and sleep
quality. We also carried out a study with a special focus: to analyse the effects of depression as
a potential confounder. The main hypothesis was that differences in cognitive performance
between groups could perhaps be explained by depression for most cognitive domains but that
some of them would also show a specific effect attributable to fibromyalgia. We were also inter-
ested in studying the possible effects of interaction between depression and fibromyalgia.
Materials and methods
Study design and setting
The study received the approval of the institutional ethics committee and the research was per-
formed in accordance with the Helsinki Declaration. Written informed consent was obtained
from all participants prior to their taking part in the study. We developed a matched case-con-
trol cross-sectional study including women from 30 to 55 years old who were divided into
three groups: a group of patients who had been diagnosed with fibromyalgia (FM group, 110
patients), a group of patients with a depressive disorder (Depressive group, 33 patients), and a
group of healthy subjects (Healthy group, 50 subjects). These were then matched by age (30–
34, 35–39, 40–44, 45–49 and 50–55 years old) and years of schooling (8 years, 9–10 years, 11–
12 years, 13–15 years and over 15 years of schooling). The recruitment was performed between
August 2012 and November 2014. The entire protocol was administered by two experts in neu-
ropsychology. The protocol was administered on 2 separate days for each participant, at the
same time of day and with a maximum separation of 2 weeks between the first and second ses-
sions. The tests were administered in the same order for all participants.
Participants
The common inclusion criteria were women aged 30–55 years. Patients in the FM group were
recruited at the Fibromyalgia Unit of the GSS-Hospital Universitari de Santa Maria, Lleida
(Spain). The inclusion criteria for this group was to have been diagnosed with fibromyalgia by
a rheumatologist specialised in this pathology and according to the 1990 ACR diagnosis crite-
ria and to be on stable doses of medications at the time of the study. Exclusion criteria were:
(a) history of neurological disorders or head trauma; (b) history of diagnosis of psychotic spec-
trum; (c) history of diagnosis of personality disorder; (d) history of nutritional or metabolic
disease associated with cognitive dysfunction; (e) history of dependence on psychoactive sub-
stances; (f) evidence of a low estimated IQ, with a standard score of below 85 in the Vocabulary
subtest of the Wechsler Adult Intelligence Scale 3rd edition, WAIS-III [34]; (g) ongoing treat-
ment with neuroleptic drugs; (h) cognitive impairment at the dementia level, with a score of
less than 25 on the Mini Mental State Examination [35]; (h) diagnosis of other chronic autoim-
mune rheumatic diseases; and (i) lack of fluency in the Spanish language.
Patients in the Depressive group were recruited from the Mental Health Unit of the
GSS-Hospital Universitari de Santa Maria, Lleida (Spain). The requirement for inclusion in
this group was to have been diagnosed as suffering from depression by a psychiatrist from the
Mental Health Unit, meeting the clinical criteria for Dysthymic Disorder, Major Depressive
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Disorder or Adjustment Disorder with Depressed Mood for the DSM-IV-TR, and having a
score of over 13 on the Spanish adaptation of the Beck Depression Inventory-II (BDI-II)
[36,37]. The exclusion criteria for the depressive group were not to present the specification of
melancholic characteristics or atypical characteristics in their diagnosis of mood disorder.
These patients were matched with the FM group by age, and education. In addition, they were
matched with FM patients with BDI-II higher than 13 by the severity of their depressive symp-
toms measured by the BDI-II) considering three different levels of depression: low (scores
between 14–19), moderate (scores between 20–28) and high (scores greater then 28).
Subjects from the Healthy group were selected from non-health care community settings.
The inclusion criteria for this group were: not presenting any self-reported depressive symp-
toms or memory complaints and having a score of below 13 in the BDI-II and a score of over
12 on the Spanish adaptation of the General Health Questionnaire (GHQ-28). We used the
revised score procedure (CGHQ) taking into account the chronicity of psychiatric symptoms
[38,39]. This group was then matched with the FM group by age and education level, with a
FM-Healthy ratio of 2:1.
The Depressive group and the Healthy group shared the same exclusion criteria as the FM
group with the addition of the presence of any rheumatologic diagnosis, including
Fibromyalgia.
Cognitive assessment
For the cognitive assessment, we selected a battery of neuropsychological tests that have been
related to the measurement of various components of attentional skills and executive func-
tions. These cognitive tasks are listed and categorised in Table 1, described briefly below, and
described in detail in S1 Appendix. Some tasks were administered by computer, using the Psy-
chology Experiment Building Language (PEBL): license-free psychology software available
from the program http://pebl.sf.net. Other tasks were administered with auditory or paper sti-
muli and oral responses.
Digit Span Forward [34]. This measure was used to measure short-term verbal memory.
It involved the immediate recall of increasingly longer strings of digits that were read to the
subjects.
D2 Test of Attention [40]. This test of selective attention includes 14 lines with the letters
“d” and “p” accompanied by a different number of strokes. Participants were requested to
cross out successive “d”s accompanied by two strokes on each line and to do this as quickly as
possible and within a period of 20 seconds.
Continuous Performance Test [41]. In this task, subjects had to respond by pressing a
button to target the letters presented on a computer screen, except when the letter “X”
appeared. In the present study we used the number of commission errors (when a response
was given after a letter “X” appeared on the screen) as a measure of impulsivity. The number
of omission errors (when the participant failed to respond to the target stimulus) was taken as
a measure of inattention.
Stroop Test [48]. This test uses a Word Card with 100 colour words (red, blue and green)
printed in black ink, a Colour Card with 100 Xs printed in blue, red or green ink, and a Col-
our–Word Card with 100 names of colours printed in incongruent colours. The Word Card
test provides a measure of automatic processing speed; the Colour Card test measures con-
trolled processing speed; and the Colour-Word Card test examines cognitive flexibility. In
addition, and Interference Index was also calculated by subtracting the number acquired in
the Colour–Word Card from the number recorded in the Colour Card; thix index was used as
a measure of the inhibition ability.
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Trail Making Test [49]. This was a set of visual searches and sequencing tasks involving
motor speed, attention and the ability to alternate between categories (set-shifting). In
TMT-A, subjects are asked to connect numbers consecutively (e.g., 1-2-3), whereas on
TMT-B, they must alternate between consecutive numbers and letters (e.g., 1-A-2-B). Scores
are based on the length of time taken to complete each part of the test. We used the TMTBA: a
composite score obtained by subtracting the time taken to complete part A from time taken to
complete part B.
N-back Paradigm [44]. This task, which assesses working memory, was performed by
computer. Subjects are required to monitor a continuous sequence of digits and to respond
whenever the stimulus presented is the same as the one presented in n previous trials, where n
is 1 (1-back condition), 2 (2-back condition) and 3 (3-back condition). The total scores ranged
from 0 to 18, with higher scores indicating the best performance.
Paced Auditory Serial Addition Task [45]. Subjects add up consecutive numbers rang-
ing from 1–9, which are presented by auditory tape, and respond orally with their sum. As
each digit is presented, patients sum that number to the digit that was presented before it.
There are two trials, with different presentation rates: in trial 1, the numbers are presented at
three second intervals (PASAT 3.0) and in trial 2 at two second intervals (PASAT 2.0). The
score for each trial was the number of correct responses for the 60 different combinations
presented.
Table 1. Cognitive domains assessed and neuropsychological tasks.
Cognitive Domains Neuropsychologi-cal Tests Outcomes Method of Administration
Short term verbal memory Digit Span Forward [34] Digit span Auditory / Oral
Selective Attention d2 Test of Attention [40] d2-TR Visual / Manual (Paper)
d2-TA
d2-TOT
d2-Con
Sustained Attention and Impulsivity CPT [41] CPT Omission errors Visual / Keyboard (PEBL)
CPT Comission errors
Processing Speed and Inhibition Stroop Test [42] Stroop Reading Words Visual / Oral
Stroop Color Naming
Stroop Word-Color
Stroop Interference Index
Set-Shifting Trail Making Test [43] TMTBA Visual / Manual (Paper)
Working Memory N-back [44] 1-back, correct respons. Visual / Keyboard (PEBL)
2-back, correct respons.
3-back, correct respons.
PASAT [45] PASAT 3.0 Auditory / Oral
PASAT 2.0
Response Inhibition Go-NoGo Task [46] Go errors Visual / Keyboard (PEBL)
No-Go errors
Reaction Time Go resp.
Reaction Time NoGo resp.
Abstraction BCST [47] BCST, categories Visual / Keyboard (PEBL)
Flexibility BCST, perseverative errors
Notes: CPT, Continuous Performance Test; PASAT, Paced Auditory Serial Addition Test; BCST. Berg Card Sorting Test; PEBL, Psychology Experiment Building
Language; d2-TR, total responses; d2-TA, correct answers; d2-TOT, total test effectiveness; d2 Con, Concentration index (see S1 Appendix for a more detailed
description)
https://doi.org/10.1371/journal.pone.0200057.t001
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Go-NoGo Task [46]. This is a task that requires a response inhibition, in which partici-
pants are required to watch a sequence of the letters “P” and “R” presented on a computer
screen. There were two conditions: under the first (Go condition), the participants were asked
to press a button in response to the letter “P” and to withhold their response to the letter “R”;
under the second (NoGo condition), they were asked to respond to the letter R and to with-
hold their response to the letter P.
Berg Card Sorting Test-64 [47]. The Berg Card Sorting Task (BCST) is a computerised
version of the Wisconsin Card Sorting Test for assessing the ability of the individual to change
their cognitive strategies in response to changing environmental contingencies. Participants
were asked to sort a series of cards, based on simple stimuli, which were characterised by three
relevant categories (colour, form, and number) with respect to four reference cards. The rules
for correctly sorting the cards were modified during the course of the test. Participants had to
complete a total of 48 different trials.
WAIS-III-R Vocabulary subtest. We used the vocabulary subtest from the Weschler-III
scale [34] and scaled the score to provide a measure of premorbid intelligence. The partici-
pants provided definitions of words presented in an order of increasing difficulty.
Assessment of self-reported depressive symptoms
We administered the Spanish version of the Beck Depression Inventory, BDI-II [50] to quan-
tify the severity of depressive symptoms. This contains 21 items to assess the emotional, beha-
vioural and somatic symptoms associated with depression. The range of scores is from 0 to 63
points. A total score of 13 or less is considered to indicate an absence of depression, 14–19
indicates mild depression, 20–28 indicates moderate depression and a score of 29 or more
indicates severe depression.
Assessment of anxiety symptoms and sleep quality
The Spanish version of the State-Trait Anxiety Inventory, STAI [51] was used to evaluate the
intensity of anxiety. The test includes two subscales, each composed of 20 items: the State sub-
scale measures anxiety related to a specific situation or period (at the moment of questionnaire
completion), while the Trait subscale measures relatively stable anxiety. Total scores range
from 20 to 80 for each subscale, with higher scores indicating greater anxiety. We chose the
75th percentile to normative data as our cut off for clinically significant levels of anxiety; this
corresponded to a raw score of 31 for STAI-State and a raw score of 32 for STAI-Trait [52].
The assessment of sleep quality was conducted using the Pittsburgh Sleep Quality Index
questionnaire (PSQI) adapted for Spain [53]. It differentiates between “poor” and “good”
sleep, measuring seven different areas: subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunc-
tion during the previous month. The range of scores is from 0 to 21, where higher scores indi-
cate lower sleep quality and a global sum of “5” or more indicates “poor” sleep quality.
Statistical analysis
The mean and standard deviations were calculated to describe the demographic and clinical
characteristics of the sample. A one-way ANOVA was used to assess differences between
groups. When normality could not be assumed (a Kolmogorov-Smirnov test was used to asses
this) a Kruskal-Wallis test was performed. The Bonferroni correction was also applied to adjust
for multiple comparisons. To compare the cognitive performance for each sample group, the
ANCOVA test was applied, adjusted for depression severity (BDI-II), anxiety (STAI-S,
STAI-R) and sleep dysfunction (PSQI). A secondary analysis, using linear models, was
The effect of depressive symptoms on cognition in patients with fibromyalgia
PLOS ONE | https://doi.org/10.1371/journal.pone.0200057 July 5, 2018 6 / 20
performed to evaluate the joint effects of fibromyalgia and depression, as binary covariates, on
cognitive measures. The models considered the main effects of depression and fibromyalgia
and their potential interaction. As a result, four groups of patients were implicitly considered:
subjects with both depressive symptoms and fibromyalgia; subjects with depressive symptoms
but without fibromyalgia; subjects without depressive symptoms but with fibromyalgia; and
subjects without either depressive symptoms or fibromyalgia. F-tests were used to compare the
models for each outcome and to subsequently determine the model that showed the best per-
formance. In this way, we were able to explore whether the effects observed were attributable
to depression, to fibromyalgia, to their independent combination or to their interaction. Anal-
yses were made using the SPSS 22 program for Windows (SPSS Inc.) and the R package and
setting the significance level to 5% (α = 0.05) for all of the analyses.
Results
Recruitment results and characteristics of the sample
Details of the recruitment results are shown in Fig 1. In the FM group, a total of 138 patients
were initially selected, of which 28 were subsequently excluded: 13 were ineligible because they
did not meet the entry criteria, while 5 decided not to participate due to a lack of time and
interest. A further 10 subjects left the study before completing the whole assessment protocol
due to bad health. As a result, this group was finally formed by a total of 110 subjects. In the
Depressive group, 45 subjects were screened, of whom 9 were ineligible because they did not
meet the entry criteria and 2 refused to participate; this group was therefore reduced to a total
of 33 subjects. In the Healthy control group, 62 subjects were screened, of whom 12 were ineli-
gible because they did not meet the entry criteria; this group therefore had a total of 50
subjects.
Demographic and clinical variables
The demographic and clinical characteristics of the groups are presented in Table 2. The
groups did not differ in either age or education. However, significant overall group differences
were found for Vocabulary (p = 0.005), BDI-II (p<0.001), STAI-State (p<0.001), STAI-Trait
Fig 1. Flow chart of recruitment for the study.
https://doi.org/10.1371/journal.pone.0200057.g001
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(p<0.001) and PSQI scores (p<0.001). In the FM group, 86% of subjects scored within the
range of depressive symptoms (whether mild, moderate or severe). Regarding anxiety scores,
68% of the patients in the FM Group scored within the range associated with significant levels
of anxiety, compared with 78% of patients in the Depressive Group and 4% in the Healthy
Group. Further, 99% of the patients in the FM Group were classified as a poor sleepers,
whereas 94% in the Depressive Group and 40% of the patients in the Healthy Group. Follow-
up analyses revealed that the FM Group and the Depressive Group did not differ in their
Vocabulary, BDI-II or STAI scores (p>0.05), whereas the FM Group showed higher scores in
PSQI than the Depressive Group (p = 0.005). Both FM and the Depressive group presented
higher scores in BDI-II, STAI and PSIQI scores than the Healthy group and lower scores in
the Vocabulary subtest.
There were 89 patients in the FM group and 39 in the Depression group who were receiving
pharmacological treatment (81% and 91% respectively of the total). None of the participants in
the control group were taking any medications. The drugs that they were taking corresponded
to the followings: analgesics and non-steroidal anti-inflammatory drugs (70% in the FM group
and 10% in the Depression group); antidepressants (49% in the FM group and 91% in the
Depression group); benzodiazepines (46% in the FM group and 67% in the Depression group);
and opiates (20% in the FM group and 0,03% in the Depression group). All of the participants
who were taking medication were on stable doses of treatment.
Neuropsychological performance by groups
Table 3 shows results comparing performance in neuropsychological tests for the three groups,
adjusting for depression (BDI-II), anxiety (STAI-S, STAI-T) and sleep quality (PSQI). The
groups did not significantly differ in the Digit Span, CPT errors, Stroop Reading Words and
Color Naming, TMTBA, all of n-back tasks, PASAT 3.0 and 2.0, Go-NoGo errors, Go-NoGO
time responses and BCST category tests. In contrast, differences between groups were found
in all of the d2 tasks (p<0.001), Stroop Word Color (p = 0.008), Stroop Interference Index
(p = 0.03) and BCST perseverative errors (p = 0.006). Follow-up analyses showed that the FM
group performed significantly worse than the Healthy group on the Stroop Word-Color and
the Interference Index tests (p = 0.02 and p = 0.03 respectively). Comparisons of the FM and
Depressive groups showed that the FM group performed significantly worse on the BCST per-
severative errors test (p = 0.004), but significantly better on all the D2 tasks (p<0.001).
Table 2. Demographic and clinical characteristics for samples groups.
Fibromyalgia Group (N = 110) Depressive Group (N = 33) Healthy Group (N = 50) FM–Depress. p-value a FM–Healthy p-value a
Age (years) 45.4 (5.6) 47.7 (5.6) 46.5 (6.5) 0.1 0.8
Education (years) 10.5 (2.8) 11.1 (2.9) 11.2 (3.0) 0.7 0.4
Vocabulary 38.5 (7.8) 41.4 (6.8) 42.4 (7.2) 0.2 0.007
BDI-II 26.5 (12.4) 25.7 (9.9) 3.6 (3.7) 1.0 <0.001
STAI-State 37.0 (11.0) 37.8 (9.0) 16.0 (9.5) 1.0 <0.001
STAI-Trait 35.8 (10.9) 34.6 (10.3) 12.7 (7.9) 1.0 <0.001
PSQI 11.9 (3.3) 9.9 (3.1) 4.7 (3.0) 0.005 <0.001
BDI-II. Beck Depression Inventory-second edition; STAI. State-Trait Anxiety Inventory; PSQI. Pittsburgh Sleep Quality Index
a ANOVA test with Bonferroni correction
https://doi.org/10.1371/journal.pone.0200057.t002
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Associations with fibromyalgia, depression and interactions
Given our interest in deciphering whether or not the outcomes could be exclusively attributed
to depressive symptoms, to fibromyalgia or to a combination of the two factors, we performed
a secondary analysis. This consisted of separately studying the cognitive performance of
patients with and without fibromyalgia divided into depressed and non-depressed groups. To
do this, the participants were initially separated into 2 main groups: a group of patients that
showed depressive symptoms and another group without depressive symptoms. The group
with depressive symptoms was composed of subjects from the Depressive Group and of sub-
jects from the Fibromyalgia Group with scores higher than 13 in the BDI-II. The group with
non-depressive symptoms was composed of subjects from the Healthy Group and of subjects
from the Fibromyalgia Group with scores equal to or lower than 13 in the BDI-II score. We
then re-divided each of these groups according to whether the patients had been diagnosed
with fibromyalgia or not. This gave us the following 4 subgroups: subjects with depressive
symptoms and fibromyalgia; subjects with depressive symptoms without fibromyalgia; subjects
without depressive symptoms and fibromyalgia; and subjects without depressive symptoms or
fibromyalgia. (Table 4). Then, we performed a regression analysis considering the main effects
Table 3. Comparison of performance on the cognitive tests for each group and p-values for multiple comparisons adjusted for depression, anxiety, sleep quality
and Vocabulary.
Fibromyalgia Group (N = 110) Depressive Group (N = 33) Healthy Group (N = 50) a FM–Depress a FM–Healthy
Digit span 4.8 (0.9) 4.8 (0.9) 5.4 (1.0) 1.0 1.0
d2-TR 435.6 (90.0) 355.4 (80.3) 477.5 (87.3) <0.001 0.6
d2-TA 165.9 (41.0) 134.1 (43.3) 185.4 (39.1) <0.001 0.6
d2-TOT 415.2 (87.3) 335.4 (86.3) 446.2(106.3) <0.001 0.3
d2-Con 163.8 (41.5) 131.2 (43.8) 182.6 (40.0) <0.001 0.5
CPT Omission errors 4.0 (8.3) 2.2 (2.4) 1.0 (1.7) 1.0 1.0
CPT Commission errors 3.5 (1.8) 4.1 (2.3) 3.1 (2.3) 0.3 0.7
Stroop Reading Words 97.8 (15.3) 92.1 (16.9) 109.3 (15.2) 0.1 1.0
Stroop Color Naming 65.3 (10.0) 62.1 (12.4) 75.2 (10.6) 0.4 0.2
Stroop Word-Color 37.5 (8.8) 35.7 (9.9) 46.6 (8.2) 1.0 0.02
Stroop Interference Index 27.71 (8.90) 26.54 (8.04) 28.54 (8.08) 1.0 0.03
TMTBA 62.39 (39.0) 55.3 (38.4) 50.8 (57.7) 0.9 1.0
1-back. correct responses 16.7 (2.4) 17.2 (1.6) 17.5 (1.8) 1.0 1.0
2-back. correct responses 13.7 (4.0) 13.8 (4.1) 15.5 (2.6) 1.0 1.0
3-back. correct responses 11.1 (4.12) 11.2 (3.4) 13.3 (3.5) 1.0 0.5
PASAT 3.0 37.0 (15.4) 37.4 (12.6) 47.4 (8.7) 1.0 0.3
PASAT 2.0 23.8 (15.4) 26.0 (10.2) 34.5 (9.3) 1.0 0.6
Go errors 6.05 (4.7) 7.5 (5.9) 4.4 (3.4) 0.2 0.5
No-Go errors 1.3 (1.8) 1.4 (1.8) 0.7 (1.0) 1.0 0.3
Reaction Time Go responses 557.3 (87.0) 549.1 (84.0) 521.5 (47.7) 1.0 1.0
Reaction Time NoGo responses 621.3 (95.0) 610.9 (83.6) 590.1 (64.0) 1.0 1.0
BCST. categories 2.7 (1.3) 2.9 (1.3) 2.7 (1.2) 1.0 0.02
BCST. perseverative errors 13.3 (5.9) 9.6 (4.6) 11.4 (5.1) 0.004 1.0
Notes: CPT, Continuous Performance Test; PASAT, Paced Auditory Serial Addition Test; BCST. Berg Card Sorting Test; d2-TR, total responses; d2-TA, correct
answers; d2-TOT, total test effectiveness; d2 Con, Concentration index
a ANCOVA test adjusted for BDI-II, STAI-S, STAI-T and PSQI scores applying Bonferroni correction
Values are raw scores
https://doi.org/10.1371/journal.pone.0200057.t003
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and their potential interaction. First, results showed that some variables were not associated
with either fibromyalgia or depression, TMTBA, 1-back, Go errors and reaction Time Go (F-
test p-values >0.05 all). Second, some variables were only associated with depression, Digit
Span, CPT Omission and Commission errors, 2-back, 3-back, PASAT 3.0, PASAT 2.0, NoGo
errors and Reaction Time NoGo responses (F-test p-values 0.0005, 0.01, 0.08, 0.01, 0.001,
0.00004, 0.00002, 0.02 and 0.02, respectively). Third, a number of variables were associated
with both fibromyalgia and depression, although without interaction, i.e. with and indepen-
dent effect, d2-TA, d2-TOT and d2-Con (F-test p-values 0.003, 0.0004 and 0.002 respectively).
Finally, an interaction between depression and fibromyalgia was detected for the d2-TR,
Stroop Reading Words, Stroop Color Naming, Stroop Word-Color, Stroop Interference
Index, BCST categories and BCST perseverative errors tests (F-test p-values 0.03, 0.003, 0.001,
0.004, 0.02, 0.03, 0.01 respectively). Detailed description of Table 4 including the beta values is
presented in S1 Table.
Table 4. Mean and standard deviations for cognitive tests in patients with and without fibromyalgia separately in subjects with and without depressive symptoms.
Not associated WITH DEPRESSIVE SYMPTOMS WITHOUT DEPRESSIVE SYMPTOMS A B C
FM n = 96 No-FM n = 33 p-valuea FM n = 14 Non-FM n = 50 p-valuea p-valueb
TMTBA 62.49 (38.5) 55.30(38.4) 0.29 61.69 (44.1) 50.80 (57.70) 0.21 0.28 0.28 0.82
1-back. correct responses 16.73 (2.4) 17.18 (1.6) 0.28 16.28 (2.5) 17.48 (1.8) 0.02 0.26 0.06 0.34
Go errors 6.23 (4.8) 7.48 (5.90) 0.41 4.77 (3.4) 4.39 (3.4) 0.59 0.15 0.12 0.06
Reaction Time Go responses 553.98 (82.3) 549.07(84.1) 0.76 581.05 (83.1) 521.56 (47.7) 0.01 0.23 0.18 0.23
CPT Commission errors 3.51 (1.8) 4.08 (2.3) 0.32 3.19 (1.8) 3.08 (2.3) 0.50 0.08 0.31 0.38
Associated only with depression
Digit span 4.8 (0.9) 4.82 (0.9) 0.71 4.93 (0.8) 5.42 (1.0) 0.08 <0.001 0.3 0.16
CPT Omission errors 4.30 (8.8) 2.24 (2.4) 0.84 1.79 (2.6) 1.03 (1.7) 0.41 0.01 0.14 0.59
2-back. correct responses 13.67 (4.1) 13.82 (4.1) 0.84 14.07 (3.1) 15.48 (2.6) 0.13 0.01 0.39 0.35
3-back. correct responses 11.01 (4.2) 11.21 (3.4) 0.84 11.86 (3.7) 13.3 (3.6) 0.19 0.001 0.37 0.38
PASAT 3.0 36.63 (15.5) 37.39 (12.6) 0.92 39.21 (14.5) 47.42 (8.7) 0.08 <0.001 0.18 0.13
PASAT 2.0 23.21 (15.1) 25.97 (10.2) 0.54 27.5 (17.1) 34.47 (9.3) 0.14 <0.001 0.07 0.38
No-Go errors 1.40 (2.1) 1.39 (1.8) 0.99 0.77 (0.6) 0.72 (1.0) 0.31 0.02 0.95 0.94
Reaction Time NoGo respon 619.04 (96.8) 610.90 (83.6) 0.78 637.20 (80.1) 590.14 (63.8) 0.01 0.02 0.95 0.94
Associated with depression and fibromyalgia
d2-TA 162.36 (40.9) 134.15 (43.3) <0.001 189.5 (39.4) 185.44 (39.1) 0.83 <0.001 0.003 0.1
d2-TOT 407.83 (86.8) 335.36 (86.3) <0.001 463.28 (77.5) 446.22 (106.3) 0.84 <0.001 <0.001 0.1
d2-Con 160.02 (40.7) 131.18 (43.8) 0.001 188.35 (39.3) 182.56 (40.0) 0.74 <0.001 0.002 0.12
Depression interacting with fibromyalgia
d2-TR 428.82 (89.8) 355.39 (80.3) <0.001 480.21 (78.8) 477.46 (87.3) 0.90 <0.001 0.0005 0.03
Stroop Reading Words 97.83 (15.1) 92.15 (16.9) 0.23 97.92 (17.2) 109.28 (15.2) 0.055 <0.001 0.87 0.003
Stroop Color Naming 65.23 (10.1) 62.21 (12.4) 0.22 65.5 (9.6) 75.16 (10.6) 0.003 <0.001 0.62 0.001
Stroop Word-Color 39.00 (5.6) 37.03 (6.9) 0.35 39.13 (5.7) 44.42 (5.9) 0.005 <0.001 0.42 0.004
Stroop Interference Index 27.86 (9.0) 26.55 (8.0) 0.18 26.64 (8.6) 28.54 (8.1) 0.005 <0.001 0.46 0.02
BCST categories 2.62 (1.2) 2.97 (1.3) 0.17 3.36 (1.2) 2.69 (1.2) 0.09 0.54 0.89 0.03
BCST perseverative errors 13.74 (5.9) 9.61 (4.6) <0.001 10.45 (5.1) 11.46 (5.1) 0.47 0.12 0.007 0.01
a p-values from a t-test comparing FM and non-FM group
bp-values from F-test comparing (A) the null linear regression model and the linear regression model with the main effect of depression, (B) the linear regression models
with the main effect of depression and with the main effects of depression and fibromyalgia; and (C) the linear regression models with the main effects of depression and
fibromyalgia and their interaction, are also shown
Values are raw scores
https://doi.org/10.1371/journal.pone.0200057.t004
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Fig 2 allows us to see the performance in cognitive tests distinguishing between patients
with and without fibromyalgia and who were depressed and non-depressed. In this way, we
were able to ascertain that: neither fibromyalgia nor depression were associated with TMTBA
performance (A); depression was the only factor associated with performance in the PASAT
Fig 2. Mean comparisons in cognitive tests, separating patients with and without fibromyalgia and those who were depressed and non-depressed. These
figures show the 4 different scenarios: A) no effect; B) an effect associated with depression; C) an effect associated with both depression and fibromyalgia; D) an
effect associated with the interaction between the two.
https://doi.org/10.1371/journal.pone.0200057.g002
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2.0 (B); both fibromyalgia and depression were associated with performance in d2TA (C); and,
depression and fibromyalgia showed interaction in the Stroop Interference Index, indicating
that the effect of fibromyalgia in this measurement depended on whether the subject showed
signs of depression or not (D).
Discussion
In this study, we provide new evidence to further our understanding of the effects of FM on
cognitive performance. We have done this separating the attributable effects of potential con-
founding variables and, in particular, the effects explained by depressive symptoms, and by
also taking into account the influence of anxiety and sleep dysfunction.
First, and as expected, a very large discrepancy was found between the FM and Healthy
groups with respect to measurements relating to depression, anxiety and sleep quality. The FM
group showed high levels of depression, anxiety and sleep dysfunction: 86% of subjects scored
within the range of depressive symptoms, 68% within the range associated with significant lev-
els of anxiety and 99% showed poor sleep quality. These results agree with those of the vast
majority of studies undertaken with FM patients: exhibiting a high presence of anxiety, depres-
sive and sleep disorders in this population [18,54–56]. In contrast, the FM and Depressive
groups did not differ in their depressive and anxious symptoms, although the FM group exhib-
ited worse sleep quality than the Depressive group. This finding was in line with Choy [57],
who suggested that sleep dysfunction might be pathogenic in fibromyalgia. This is also impor-
tant because it has been identified as one of the main domains interfering with patient quality
of life [58].
With regard to the specific objectives of the study in terms of cognitive performance, the
first finding was that the differences initially found between the FM and the Healthy groups in
the majority of the cognitive measurements subsequently disappeared when we adjusted for
depression, anxiety and sleep quality, leaving only differences in the Stroop Interference task.
This lack of difference in most of the cognitive tests supports our main hypothesis that the dif-
ferences in cognitive performance between groups could mainly be explained by depression
for most cognitive domains. Moreover, this is also in line with earlier studies that showed no
significant differences in the cognitive performance of patients with fibromyalgia when
depression components were controlled [10,22,59]. The results presented by Sletvold [11] and
Landrø [12], who also studied cognitive performance in FM patients, comparing their perfor-
mance with those of a healthy control group and a group of patients with Major Depression,
ran along the same lines. They found that both patients with FM and depression shared a non-
specific deficit in their capacity to process information and long-term recall memory. Even so,
other studies involving FM patients failed to find any relationship between the intensity of the
depressive symptoms and cognitive performance [4,23,25,33,60]. It is also worth mentioning
the fact that there were significant methodological differences between these studies and our
own, as many of the previous studies did not include patients with depression, whether
because this had been an exclusion criterion or because the intensity of the depressive symp-
toms had been either null or mild over their whole sample. As a result, those samples were dif-
ferent from ours and it is not, therefore, strange to find different results. Our experience in
working with patients with FM leads us to believe that the high proportion of depressive symp-
toms found in the patients who participated in our study should not be regarded as unusual.
The association identified in this study in the Interference task of the Stroop Test had also
been previously demonstrated in other studies involving patients with FM. Martinsen et al
[61] found pronounced differences between FM patients compared to healthy controls in the
incongruent condition with respect to the congruent condition of this same task. This was also
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associated with a reduced activation of the caudate nucleus, lingual gyrus, temporal areas and
the hippocampus in FM patients. Similarly, Mercado et al [62] found a significant emotional
Stroop interference effect in FM patients when recording their brain activity with event-related
potentials. The results of this study revealed that the cognitive inhibition associated with a very
automatic response elicited greater prefrontal neural activity when symptom-related stimuli
were processed. These results were only observed for the FM group which led the authors to
suggest a specific difficulty in cognitive inhibition in fibromyalgia patients under conditions
linked with their disease. These results highlight the problems identified in this population
with respect to the ability to detect conflicts and automatically inhibit unwanted irrelevant
responses. This is a capacity that allows individuals to regulate information processing in
order to deal with a concurrent task and constitutes a central component of executive control
and one that is critical for inhibiting response tendencies [63].
The second important finding of this study concerns the comparison between the FM and
Depressive groups with respect to cognitive performance. Both groups showed similar levels of
performance in most of the cognitive tests, with the exception of measures of selective atten-
tion and flexibility. The Depressive group showed the worst performance in all of the tasks in
the d2 Test of Attention. Several previous studies have identified cognitive dysfunction in
depressed patients, especially affecting the domains of attention, memory, psychomotor speed,
processing speed and executive function [19–21]. The FM group also showed a greater number
of perseverative errors in the BCST test than the Depressive group, suggesting that this could
be a specific dysfunction related to fibromyalgia. The results from Walteros et al. [59] were
similar; they found that FM patients displayed more perseveration errors in CALT, an experi-
mental learning task designed to assess the acquisition of arbitrary associations between targets
and colours [64]. This impairment of cognitive flexibility in fibromyalgia patients would also
be compatible with passive and maladaptive coping responses that have been described in indi-
viduals with pain-related conditions [65].
The secondary analysis performed in this study to separately evaluate the effects of depres-
sion and fibromyalgia on cognitive tests allowed us to refine our main hypothesis that differ-
ences in cognitive performance between groups could be explained by depression for most
cognitive domains but that some would exhibit a specific effect attributable to fibromyalgia.
Based on the results of this secondary study, and taking into account the high comorbidity
between fibromyalgia and depression, FM patients might be expected to perform more poorly
on tasks involving short term memory, working memory, selective attention, flexibility, pro-
cessing speed, inhibition and flexibility. Some of this impaired performance seems to be
related to depression (short term memory, working memory and inattention), other parts to
the additive effect of FM and depression (selective attention) and the rest to the effects of inter-
action between FM and depression (processing speed, inhibition and flexibility). Some of this
impaired performance would be related to depression (short term memory, working memory
and inattention), other to the additive effect of FM and depression (selective attention) and the
rest to the interactive effect of FM and depression (processing speed, inhibition and flexibility).
Special attention should be given to these significant interactions and their interpretation: the
effect of depression in these cognitive tasks is different depending on whether or not the per-
son has FM. The final result did not, therefore, correspond to the sum of these 2 factors, but
had an effect of its own. In d2TR, a selective attention task that also measured processing
speed, we found that patients with FM and depression performed better than those without
FM and depression. This suggests that FM could have acted as a protector against the clearly
negative effects of depression as far as processing speed and selective attention were con-
cerned. It would thus have minimised the effects that depression could have had on its own.
This was not, however, maintained in the rest of tasks that also measured this function, such as
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the Stroop Reading Words and Stroop Word Colors tests. In these tasks, the main differences
were found in the non-Depression group. In them, the patients with FM showed the worst lev-
els of performance. However, this poor result was not maintained in the group of people with
depression; they did not present any significant differences in performance for this task. This
may suggest that when depression is present, the effects of FM are matched by those of depres-
sion, but when there is no depression, the deleterious effects of FM are clearly visible. Similar
conclusions were drawn in relation to inhibition as measured by the Stroop Interference
Index. Finally, In the BCST perseverative errors task, the patients who showed the worst per-
formance (those who produced the most perseverative errors) were the ones with both FM
and depression. In the group without depression, on the other hand, there were no observable
differences in the number of errors, whether the patients had FM or not. Although the reasons
for these findings are likely to require further analysis, all of the interactions observed con-
firmed that the effects of the two key factors: depression and FM, should not be minimized.
The possible effects of interactions between them should therefore be considered. What is
more, these interactions could explain some of the discordances found between the results of
different studies undertaken with this population, particularly considering that interactions
between different variables have hardly ever been analyzed. This factor may also help to
explain the high level of heterogeneity identified in these patients. To the best of our knowl-
edge, this is a novel finding, although further studies will be required to validate these results.
No differences were identified in the performance of the participants with respect to the cogni-
tive load of the tests administered. This contrasted with the findings from another recent work
carried out by the same authors [66].
One of the strengths of our study was that it included a reasonable range of neuropsycho-
logical tasks covering the main attentional and executive areas; another was the sample size,
which was larger than in previous studies. Moreover, the design of this study allowed us to sep-
arate the effects of potential confounder variables from FM in relation to cognitive perfor-
mance and to study interactions between different variables.
However, our study also presents some methodological limitations. First, there may have
been a degree of selection bias, because it was not possible to randomize the selection of partic-
ipants; instead, it was the subjects themselves who decided whether or not to participate in the
study. Even so, it is worth mentioning that refusal to participate in the study was minimal, in
both the patient and control groups, as was the loss of cases during the assessment. Further,
the present study only recruited women; this allowed us to provide greater homogeneity in the
sample, but future studies should be replicated including men with fibromyalgia. Second, this
is a case-control study and, therefore, only statistical association can be studied. No causality
can be attributed to the explanatory variables (mainly fibromyalgia and depression) on the
responses. Third, it is also important to remark that when we designed this study, we were
aware of the unfeasibility of including the same number of controls than cases given that fibro-
myalgia patients exhibit a lower educational level than the general population. Given that the
performance on cognitive tasks is related to the educational level, we were interested to focus
on recruiting the largest number of cases, taking into account our actual possibilities, and
matching pairs of them with one single control. However the statistical results obtained with
the proposed design shows that we achieved enough power to solve our hypothesis. Further-
more, the matching ratio of cases with patients with depression was 3:1, given once again the
unfeasibility of a 1:1 ratio which could have caused an increase of the type II error, with a con-
sequent loss of statistical power. That said, the present study may well reflect the current reality
of FM patients, and the fact that the control group was enriched with patients with depression
allowed us to assess the effects of FM itself, having previously adjusted for depression. Larger
observational studies including non-depressed FM patients should also be undertaken. In our
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study we limited our work to evaluating the presence or absence of a potential interaction
between fibromyalgia and depression in the responses. In this respect, beta values and F statis-
tics could also have been presented in Table 4, in addition to p-values, for interpretation pur-
poses. We have intentionally omitted this information for the sake of simplicity; we believe
that this deeper level of analysis could be reserved for future work, which would ideally include
an increased sample size and perhaps also the fitting of non-linear models. Finally, we must
also discuss the possible limitations associated with a lack of control over medication that the
patients were taking, having excluded patients who were taking treatment with neuroleptics
but allowing treatment with anxiolytic agents and antidepressants. It is important to note,
however, that treatment with anxiolytics was at low doses for all patients. Further, the present
study has specifically focused on analyzing the effect of depression as a potential confounder
in the cognitive performance of patients with fibromyalgia. However, future studies should
also include an in depth analysis of the role of anxiety as this is a symptom with a high preva-
lence in this disease and one that also has significant repercussions on cognitive functions.
In summary, these results lead us to conclude that fibromyalgia patients show characteristic
cognitive dysfunction in their attentional and executive domains. While many of these can be
explained by the effects of depressive symptoms, some others seem to also depend on the
effects of fibromyalgia. More specifically, we found that short-term auditory memory, working
memory and inattention scores were all associated with depression alone, whereas selective
attention was associated with both depression and fibromyalgia, and processing speed, cogni-
tive flexibility and inhibitory control showed significant interactions between depression and
fibromyalgia.
From a clinical practice perspective, we must consider emotional symptoms, such as
depression and anxiety, to be an essential part of the cognitive performance of patients with
fibromyalgia; it therefore makes no sense to analyze them separately. All these results suggest
that improving emotional symptoms in this population would reduce the impairment of atten-
tional processes even though impairment of cognitive flexibility and inhibition would still
remain. Our findings also highlight the importance of clinicians understanding this pattern of
cognitive dysfunction in order to provide a specific approach that could be used to address
both the emotional and cognitive domains and thus help to improve the cognitive perfor-
mance of those suffering from fibromyalgia.
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